JP2008535860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535860A5 JP2008535860A5 JP2008505617A JP2008505617A JP2008535860A5 JP 2008535860 A5 JP2008535860 A5 JP 2008535860A5 JP 2008505617 A JP2008505617 A JP 2008505617A JP 2008505617 A JP2008505617 A JP 2008505617A JP 2008535860 A5 JP2008535860 A5 JP 2008535860A5
- Authority
- JP
- Japan
- Prior art keywords
- amphetamine
- lysine
- compound
- pharmaceutical composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 229940024606 amino acid Drugs 0.000 claims 14
- 235000001014 amino acid Nutrition 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 14
- VOBHXZCDAVEXEY-JSGCOSHPSA-N lisdexamfetamine Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 VOBHXZCDAVEXEY-JSGCOSHPSA-N 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 10
- CETWSOHVEGTIBR-FORAGAHYSA-N (2s)-2,6-diamino-n-[(2s)-1-phenylpropan-2-yl]hexanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 CETWSOHVEGTIBR-FORAGAHYSA-N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 8
- 229940025084 amphetamine Drugs 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 7
- 229960001681 croscarmellose sodium Drugs 0.000 claims 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 7
- 235000019359 magnesium stearate Nutrition 0.000 claims 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 229960000632 dexamfetamine Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 206010016256 fatigue Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 2
- 206010000117 Abnormal behaviour Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000001573 Cataplexy Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 235000019766 L-Lysine Nutrition 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- -1 L-lysine-glycine-d-amphetamine Chemical compound 0.000 claims 1
- 229930182821 L-proline Natural products 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 206010024264 Lethargy Diseases 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000005439 Sleep paralysis Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 229960001252 methamphetamine Drugs 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 229960001344 methylphenidate Drugs 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Chemical group 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 229960002429 proline Drugs 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66938505P | 2005-04-08 | 2005-04-08 | |
| US66938605P | 2005-04-08 | 2005-04-08 | |
| US68117005P | 2005-05-16 | 2005-05-16 | |
| US75654806P | 2006-01-06 | 2006-01-06 | |
| US75995806P | 2006-01-19 | 2006-01-19 | |
| PCT/US2006/013221 WO2006121552A2 (en) | 2005-04-08 | 2006-04-10 | Abuse-resistant amphetamine prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535860A JP2008535860A (ja) | 2008-09-04 |
| JP2008535860A5 true JP2008535860A5 (cg-RX-API-DMAC7.html) | 2011-11-10 |
Family
ID=37397039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505617A Pending JP2008535860A (ja) | 2005-04-08 | 2006-04-10 | 乱用抵抗性アンフェタミンプロドラッグ |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1865980A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008535860A (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0612440A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2603873A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007012507A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006121552A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009035473A2 (en) * | 2007-09-13 | 2009-03-19 | Sanfilippo Louis C | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders |
| US8487134B2 (en) | 2008-10-09 | 2013-07-16 | Archimica, Inc. | Process for the synthesis of amphetamine derivatives |
| GB201002612D0 (en) * | 2010-02-16 | 2010-03-31 | Jagotec Ag | Improvements in or relating to organic compounds |
| US20140073589A1 (en) * | 2012-06-27 | 2014-03-13 | Shire Ag | Amphetamine Prodrugs |
| WO2018118903A1 (en) | 2016-12-19 | 2018-06-28 | The Regents Of The University Of California | Noncrushable pill formulatiions |
| WO2018118902A1 (en) | 2016-12-19 | 2018-06-28 | The Regents Of The University Of California | Dual-enzyme responsive peptides |
| DK3459538T3 (da) | 2017-09-20 | 2020-08-03 | Sandoz Ag | Krystallinske salte af et dextroamfetamin-prodrug |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| JP2022529781A (ja) | 2019-04-17 | 2022-06-24 | コンパス パスファインダー リミテッド | サイロシビンによるうつ病及び他の様々な障害の治療 |
| EP4098248A1 (en) * | 2019-12-30 | 2022-12-07 | Labomed Pharmaceutical Company S.A. | Oral solutions comprising lisdexamfetamine salts |
| JP2023549405A (ja) | 2020-11-18 | 2023-11-24 | マインド メディシン， インコーポレイテッド | 心理療法を補助するためのｍｄｍａプロドラッグ |
| EP4447891B1 (en) | 2021-12-16 | 2025-10-01 | Labomed Pharmaceutical Company S.A. | Container comprising a lisdexamfetamine containing oral solution |
| EP4561528A1 (en) | 2022-07-29 | 2025-06-04 | Labomed Pharmaceutical Company S.A. | Lisdexamfetamine containing oral solution |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3878187A (en) * | 1972-09-11 | 1975-04-15 | Syva Co | Polypeptide derivatives of amphetamine and analogs for immunoassays |
| US6384020B1 (en) * | 1999-07-14 | 2002-05-07 | Shire Laboratories, Inc. | Rapid immediate release oral dosage form |
| IL158959A (en) * | 2001-05-25 | 2010-06-30 | Cephalon Inc | Solid pharmaceutical formulations comprising modafinil |
| US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| EA008864B1 (ru) * | 2003-09-30 | 2007-08-31 | Нью Ривер Фармасьютикалз Инк. | Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств |
-
2006
- 2006-04-10 BR BRPI0612440-2A patent/BRPI0612440A2/pt not_active Application Discontinuation
- 2006-04-10 CA CA002603873A patent/CA2603873A1/en not_active Abandoned
- 2006-04-10 WO PCT/US2006/013221 patent/WO2006121552A2/en not_active Ceased
- 2006-04-10 MX MX2007012507A patent/MX2007012507A/es unknown
- 2006-04-10 JP JP2008505617A patent/JP2008535860A/ja active Pending
- 2006-04-10 EP EP06769808A patent/EP1865980A4/en not_active Withdrawn